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Using antibodies generated to the C-terminal 41 amino acids of the cloned rat 
kappa receptor, the present study examines the distribution of the kappa1 
receptor-like immunoreactivity (li) using immunohistochemical techniques. 
The localization of the kappa1 receptor staining generally corresponds well to 
previous receptor binding and in situ hybridization studies, with stained fibers 
and/or  cells observed in such regions as the endopiriform nucleus, claustrum, 
nucleus accumbens, olfactory tubercle, bed nucleus stria terminalis, medial 
preoptic area, paraventricular, supraoptic and lateral hypothalamus, median 
eminence, thalamus, medial amygdala, parabrachial nucleus, nucleus of the 
solitary tract, and the superficial layers of the spinal cord. This localization is 
consistent with the wide range of functions associated with kappa1 receptors, 
including analgesia and hormonal regulation. 
The kappa opioid receptor, one of three receptor types found in the central nervous 
system, has been implicated in a number of behaviors and functions, including 
analgesia, electrolyte balance, hormonal regulation, and the modulation of reward 
pathways. The recent cloning of the kappa1 receptor (1,2) suggests it is a member of the 
seven transmembrane family of receptors that is negatively linked to adenylate cyclase. 
In situ hybridization studies (3) suggest an excellent correspondence between the 
kappa1 mRNA and receptor binding, with differences in localization due in part to 
receptor transport. To further examine the anatomical distribution of the kappa1 
receptor in the rat, selective antibodies were raised and immunohistochemical studies 
were performed to localize the kappa1 receptor protein. 
Antibody Production. A 242bp fragment (1098-1340) of the rat kappa1 receptor (1) 
was subcloned into the pGEX-kg protein expression vector (4). This plasmid, when 
expressed in bacteria (JM101), produces a glutathione S-transferase (GST)-kappal 
receptor fusion protein which can be purified from crude bacterial extracts using 
glutathione affinity chromatography (5). The portion of the kappa1 receptor that is 
expressed with this construct corresponds to the terminal 41 amino acids of the rat 
kappa1 receptor, a region which shows little amino acid homology to the cloned mu and 
delta receptors (6-9). Antibodies were generated by inoculating rabbits (New Zealand 
White) with 250 ~tg of the kappa1 receptor-fusion protein suspended in Freund's 
adjuvant using a standard injection schedule. The resulting rabbit serum was affinity 
purified using the terminal 41 amino acid kappa1 receptor protein coupled to a 
sepharose-4B-cyanogen bromide column. 
Immunohistochemistry. Male Sprague-Dawley rats (n = 4) were perfused 
transcardially with 0.9% saline followed by Zamboni's fixative. Brains were removed 
from the skull, postfixed in Zamboni's fixative (24 h), sectioned on a Jung microtome (30 
~) and immunohistochemically stained using standard methods (10). Floating sections 
were washed in 50 mM KPBS, incubated with 0.3% H202 (30 min), rinsed in 50 mM 
KPBS and incubated for 96 h with the kappa1 receptor antibody (1:1000, diluted in 50 
mM KPBS, 0.4% Triton, 1% BSA, 1% normal goat serum) at 4°C. After washing with 50 
mM KPBS, sections were incubated with biotinylated goat anti-rabbit (1:200, 1 h, 22°C), 
followed by an avidin-biotin complex coupled to HRP (1:200, 1 h, 22°C, Vector Elite). 
The HRP reaction product was visualized by DAB with nickel chloride enhancement. 
Immunohistochemical controls included the co-incubation of the kappa1 antibody with 




Figure 1. Kappa1 receptor immunohistochemical staining in the paraventricu- 
lar nucleus (PVN) of the hypothalamus (A). Kappa1 receptor staining is ob- 
served in fibers and terminals of the PVN, as well as in the magnoceUular cells 
indicated by arrows. Panel B shows a hypothalamic section in which the 
kappa1 antibody was coincubated with 1.2 ~M of the fusion protein. This 
control demonstrates that the immunohistochemical staining is specific and 
can be blocked by the kappa1 receptor fusion protein. Size bar = 100 p.m. 
The distribution of the kappa1 receptor immunoreactivity is consistent with pre- 
vious receptor binding and in situ hybridization studies (3). Immunohistochemical 
staining was observed in regions including the endopiriform nucleus, claustrum, nu- 
cleus accumbens, olfactory tubercle, bed nucleus stria terminalis, medial preoptic area, 
paraventricular, supraoptic and lateral hypothalamus, paraventricular and central nu- 
cleus of the thalamus, medial amygdala, superior and inferior colliculi, parabrachial nu- 
cleus, the nucleus of the solitary tract and the superficial layers of the spinal cord. In the 
nucleus accumbens, differences in staining were seen in the accumbens core vs. shell re- 
gions, with more intense kappa1 receptor staining in the lateral and septal pole regions 
of the nucleus accumbens shell. In the paraventricular nucleus of the hypothalamus 
(Fig. 1), kappa1 staining is observed in scattered fibers and in the magnocellular neu- 
rons. These neurons project directly to the neural lobe via the internal layer of the me- 
dian eminence, which also demonstrates dense kappa1 receptor immunohistochemical 
staining. The localization of kappa1 receptor staining in the paraventricular and 
supraoptic nuclei as well as the internal layer of the median eminence, provides an 
anatomical basis for the inhibitory effects of kappa agonists on vasopressin and oxy- 
tocin release. 
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